Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
ResMed Inc has announced a proposed sale of securities under Rule 144, with a director, Peter C. Farrell, planning to sell 945 common shares through Merrill Lynch. This move follows previous sales of 6,000 shares over the past three months, indicating a continued divestment by the director. The sale is scheduled for July 2, 2025, and could potentially impact the company’s stock market performance and investor sentiment, given the significant role of the director in the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc is a company operating in the healthcare industry, primarily focusing on the development and manufacturing of equipment related to sleep disorders, particularly sleep apnea. The company’s market focus includes providing innovative solutions for respiratory care and improving the quality of life for patients with chronic respiratory conditions.
Average Trading Volume: 1,170,006
Technical Sentiment Signal: Buy
Current Market Cap: A$57.19B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.